Emre Yekeduz, MD

Articles

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

David Spigel, MD;Thach-Giao Truong, MD;Emre Yekeduz, MD;Paolo Tarantino, MD;John Strickler, MD

September 11th 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Dr Yekedüz on a Case Study of Adjuvant Treatment Options in ccRCC

Emre Yekeduz, MD

September 4th 2024

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

Dr Yekedüz on the Importance of the KEYNOTE-564 Trial in Adjuvant ccRCC

Emre Yekeduz, MD

August 27th 2024

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Dr Yekedüz on the Benefits of Biomarker-Driven Treatment in Kidney Cancer

Emre Yekeduz, MD

August 26th 2024

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

From Bench to Bedside: HIF-2α Inhibition in RCC

Clara Steiner, MD;Emre Yekeduz, MD;Toni Choueiri, MD

August 22nd 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.